CD45RB mAb

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD45RB mAb
Drug Alias Namemonoclonal (RCT/Abgenix/Amgen)MAb (RCT/Abgenix)CD45RB MAb (RCT/Abgenix)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLeukocyte common antigen inhibitors
TargetsLeukocyte common antigen
Therapy Area/IndicationsRejection of organ transplantationAutoimmune DiseasesMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesResearch Corporation Technologies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesResearch Corporation TechnologiesAmgen IncAbgenix Incorporated
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune DiseasesMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A